D-ENANTIOMERIC PEPTIDES FOR ANTI-INFLAMMATORY TREATMENT OF AMYOTROPIC LATERAL SCLEROSIS (ALS) AND OTHER DISEASES DRIVEN BY NEURO-INFLAMMATION
The present invention relates to a polymer comprising at least one monomer, the at least one monomer comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 or homologs with an identity of at least 80% thereof, and a pharmaceutical composition comprising such a peptide for use in the treatment of amyotrophic lateral sclerosis (ALS).
1 .- 14 . (canceled)
15 . A method of treating amyotrophic lateral sclerosis (ALS), wherein the method comprises administering to a patient afflicted by ALS a polymer which comprises at least one monomer comprising a peptide having an amino acid sequence selected from SEQ ID NO: 1 and homologs with an identity of at least 80% thereof in an amount which is effective for treating ALS.
16 . The method of claim 15 , wherein the amino acid sequence selected from SEQ ID NO: 1 and homologs with an identity of at least 80% thereof is amidated.
17 . The method of claim 15 , wherein the at least one monomer comprises a peptide having an amino acid sequence selected from SEQ ID NO: 1 (RD2 monomer) and homologs with an identity of at least 90% thereof.
18 . The method of claim 17 , wherein the amino acid sequence selected from SEQ ID NO: 1 and homologs with an identity of at least 90% thereof is amidated.
19 . The method of claim 15 , wherein the peptide comprises from 2 to 10 monomers.
20 . The method of claim 15 , wherein the peptide comprises 2 monomers.
21 . The method of claim 15 , wherein the peptide comprises identical monomers.
22 . The method of claim 15 , wherein the peptide comprises non-identical monomers.
23 . The method of claim 15 , wherein the peptide comprises a dimer of two RD2 peptides.
24 . The method of claim 15 , wherein the polymer comprises or consists of a peptide having amino acid SEQ ID NO: 2 (RD2RD2).
25 . The method of claim 15 , wherein the peptide consists substantially of D-amino acids.
26 . The method of claim 15 , wherein the peptide is linked to a further substance.
27 . The method of claim 15 , wherein the monomers are covalently linked to one another.
28 . The method of claim 15 , wherein the monomers are non-covalently linked to one another.
29 . The method of claim 15 , wherein the monomers are linked to one another directly without a linker group.
30 . The method of claim 15 , wherein the monomers are linked to one another indirectly through a linker group.
31 . The method of claim 15 , wherein the monomers are linked to one another in a linear fashion.
32 . The method of claim 15 , wherein the monomers are linked to one another in a branched fashion.
33 . The method of claim 15 , wherein a dendrimer is involved or the monomers are linked to a platform molecule or are linked in a combination of these options.
34 . A pharmaceutical composition for the treatment of ALS, wherein the composition comprises (i) a polymer which comprises at least one monomer comprising a peptide having an amino acid sequence selected from SEQ ID NO: 1 and homologs with an identity of at least 80% thereof and (ii) one or more pharmaceutically acceptable excipients.